美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Xtrackers Nifty 500 India ETF

24.56

+0.02500.10%

成交量：433.00

成交額：1.07萬

市值：491.20萬

市盈率：- -

高：24.65

開：24.58

低：24.56

收：24.54

52周最高：27.40

52周最低：23.33

股本：20.00萬

流通股本：20.00萬

量比：0.03

換手率：0.22%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

九源基因(02566)：JY54注射液IND申請獲CDE正式受理

亞盛醫藥BTK降解劑APG-3288新藥臨牀申請（IND）獲CDE許可，全球臨牀開發再提速

友芝友生物-B(02496)：M 701取得FDA的IND批准

前沿生物：2025年末公司已就FB7013向國家藥監局提交IND申請並獲受理，FB7013正式進入臨牀申請審批通道

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IND"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":24.56,"timestamp":1770670800000,"preClose":24.535,"halted":0,"volume":433,"delay":0,"changeRate":0.0010189525168126587,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"已收盤","change":0.025,"latestTime":"02-09 16:00:00 EST","open":24.58,"high":24.65,"low":24.56,"amount":10655.2062,"amplitude":0.003668,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":24.535,"sharesOutstanding":200001,"nav":24.236,"aum":4847319.35,"bidAskSpread":0,"volumeRatio":0.029096},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.029096,"shares":200001,"dividePrice":0,"high":24.65,"amplitude":0.003668,"preClose":24.535,"low":24.56,"week52Low":23.3301,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":24.56,"eps":0,"divideRate":0,"volume":433,"delay":0,"ttmEps":0,"open":24.58,"prevYearClose":24.78,"prevWeekClose":24.535,"prevMonthClose":23.8555,"prevQuarterClose":24.78,"fiveDayClose":24.7868,"twentyDayClose":24.5796},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610600638","title":"九源基因(02566)：JY54注射液IND申請獲CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610600638","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610600638?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 16:56","pubTimestamp":1770627414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因 发布公告，公司自主开发的化学1类创新药JY54 注射液新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。JY54注射液是公司自主研发的一款长效胰淀素类似物。此外，在与已上市肥胖治疗药物的联合应用研究中，JY54注射液展现出显著的药物协同潜力。基于其分子设计特点及作用机制分析，JY54注射液有望支持长效给药方案，并在体重管理领域展现差异化的临床应用潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082196.USD","02566","BK4017","IND","LU1223082519.USD","LU1223083913.SGD","BK1161","CDE"],"gpt_icon":0},{"id":"2609095558","title":"亞盛醫藥BTK降解劑APG-3288新藥臨牀申請（IND）獲CDE許可，全球臨牀開發再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2609095558","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609095558?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 10:04","pubTimestamp":1770343440,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年2月6日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，公司自主研发的原创新一代布鲁顿酪氨酸激酶靶向蛋白降解剂APG-3288的新药临床申请日前已获国家药品监督管理局药品审评中心许可，拟开发用于治疗复发/难治性血液系统恶性肿瘤。此前，该药物已获美国FDA许可开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4882324_ZH82324_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06855","CDE","BK4144","LU1223082196.USD","LU1223082519.USD","TK","IND","LU1923622291.USD","BK4139","BK4017","LU2125909759.SGD","BK1161","BK1574","LU2125909916.SGD","BK4129","LU1223083913.SGD","APG","AAPG"],"gpt_icon":0},{"id":"2608824493","title":"友芝友生物-B(02496)：M 701取得FDA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608824493","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608824493?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 18:09","pubTimestamp":1770113353,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 发布公告，于2026年1月31日，注射用重组抗上皮细胞黏附分子和分化簇3人鼠嵌合双特异性抗体获美国食品药物管理局临床试验申请批准，标志着这款针对恶性胸腔积液的创新疗法迈入国际化临床开发新阶段，为全球患者带来新希望。M 701精准靶向Ep CAM和CD3，其中Ep CAM在上皮来源恶性胸腔积液肿瘤细胞中高频表达，是关键治疗靶点;CD3可激活机体抗肿瘤免疫，二者协同实现精准治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1161","02496"],"gpt_icon":0},{"id":"2606243834","title":"前沿生物：2025年末公司已就FB7013向國家藥監局提交IND申請並獲受理，FB7013正式進入臨牀申請審批通道","url":"https://stock-news.laohu8.com/highlight/detail?id=2606243834","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606243834?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 20:05","pubTimestamp":1769429100,"startTime":"0","endTime":"0","summary":"关于BD合作事宜，公司始终秉持开放的态度，积极探索符合产品发展战略的合作机会。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-26/doc-inhirukv8982872.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-26/doc-inhirukv8982872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IND","BK0239","688221"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IND\",params:#limit:6,delay:false,,,undefined,":[]}}